Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 10/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140095 | 0.92 | MAPK14 (0.52) | MAPK11MAPK14MAPK13MAPK12SMYD3 | |
| SCHEMBL1140244 | 0.91 | MAPK11 (0.55) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL1140684 | 0.91 | MAPK11 (0.55) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL1140325 | 0.90 | MAPK11 (0.54) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL1140051 | 0.90 | MAPK11 (0.54) | MAPK11MAPK14MAPK13MAPK12BRAF | |
| SCHEMBL2947726 | 0.89 | MAPK14 (0.53) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5786079 | 0.89 | MAPK14 (0.53) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL1140194 | 0.88 | MAPK11 (0.56) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5789472 | 0.88 | MAPK11 (0.52) | MAPK11MAPK14MAPK13MAPK12CNR2 | |
| SCHEMBL5785264 | 0.87 | MAPK14 (0.54) | MAPK11MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682520-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-23 | — | — | EP | disclosed |
| US-7750154-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-20070043065-A1 | Amide derivatives | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| EP-1682520-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005042502-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043065-A1 | Amide derivatives | IL6, IL2, IL1B | MAPK11 2328/4885MAPK14 2518/4885MAPK13 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.